Not provided
Not provided
Not provided
Not provided
Not provided
Participant mortality rates were higher than expected.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Center for Vaccine Development - Mali | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This study is being conducted in Mali, Africa.
Pneumonia is a respiratory infection of the lungs caused by bacteria or virus. Some children can develop signs of severe pneumonia and as a result, have difficulty breathing and low levels of oxygen in the blood. In some cases this can progress to death. Patients with signs of severe pneumonia require admission to the hospital for treatment and the treatment includes delivery of oxygen. Currently, in the hospital, oxygen is available for delivery by nasal cannula to children. In this case, oxygen is given through a small plastic tube which delivers oxygen through the nose. However, the amount of oxygen that can be given is limited because of the size of the tube and the amount of oxygen that can go through. However, a new device known as the bubble CPAP machine delivers oxygen through the nose in a way that helps the airways to stay open. This is known to provide better support to children less than 1 year of age who have difficulty breathing with signs of severe pneumonia. The purpose of this study is to evaluate the effectiveness of bubble CPAP in Children up to 5 years of age with with signs of severe pneumonia.
This study includes two cohorts. One cohort will participate in an interventional clinical trial and the other cohort will participate in an observational study.
Interventional Cohort:
The first cohort will include 600 children with signs of severe pneumonia, 1 year up to 5 years of age. Signs of severe pneumonia include fast breathing, difficulty breathing and who are very sick (not able to drink, vomiting, having seizures, are very sleepy or with severe malnutrition). Two out of every three children will receive oxygen with the bubble CPAP and one out of every three children will receive treatment with oxygen with regular nasal cannula. The treatment assignment will be determined randomly. We will follow up participants during their entire hospitalization. During this time we will collect information on the child's illness, test results and treatment.
Observational Cohort:
The second cohort will include 450 children with signs of severe pneumonia, under 1 year of age. In Mali, bubble CPAP is currently given as standard of care (when possible) for children with signs of severe pneumonia, under 1 year of age; therefore, children in this cohort will already be receiving bubble CPAP as standard of care prior to enrollment. The only research activities will be to follow the children during their hospitalization and collect information about their clinical condition, test results, treatment and the amount of oxygen required during the hospital admission.
The remainder of the information in this ClinicalTrials.gov registration will refer only to the Intervention Cohort.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bubble CPAP | Experimental |
| |
| Standard Therapy | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bubble CPAP | Device | Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater. |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment failure rate | We define treatment failure as the occurrence of any two or more of the following clinical criteria 2 hour after initiation of an intervention:
| 2 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality rate | The difference in mortality between the standard therapy group vs bCPAP group at the time of discharge. | Through hospital discharge, an average of 1 week |
Not provided
Inclusion criteria:
Cases must meet the all following inclusion criteria for eligibility to be placed on bCPAP
Hospitalization
Age 12 months up to 5 years
Fast breathing defined as: (Using a timing device to count rate for one full minute)
Any of the following respiratory signs: wheezing, nasal flaring, chest indrawing, cyanosis, grunting, head nodding, stridor and/or oxygen saturation <90%.
Informed written consent obtained Or
Age 12 months up to 5 years
Weight up to 20Kg
With cough AND/OR any sign of difficult breathing Plus ONE general danger sign as follow:
Informed written consent obtained
Patients with the following conditions who meet eligible criteria can benefit from bCPAP:
We will include patients with progression to severe pneumonia during the hospitalization and those ones with chronic diseases too.
Definitions:
Exclusion criteria:
Cases that meet any of the following exclusion criteria will be ineligible to enroll:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adnan T Bhutta, MBBS | University of Maryland, Baltimore | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Vaccine Development - Mali | Bamako | Mali |
Not provided
| ID | Term |
|---|---|
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
This is an unblinded, age-stratified, randomized trial with a 2:1 allocation ratio.
Not provided
Not provided
Not provided
Not provided
|
| Standard Therapy | Other | For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 < 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group. |
|